You are spot on here and it’s most likely that those other two patients I think one died and the other probably was very close to death and therefore it was “too late“ to give them LL and or a PDL one or PD one antagonist. Follow up studies will have a much more rigorous inclusion and exclusion criteria. I would bet the farm on that because this is a retrospective study remember including compassionate use patients, 10 patients in an MTNC trial and basket study patients.. not ideal but when compile this way to my eyes, it’s extremely compelling.